title: [Expression of Foxa2 and its early alarm value of cancerous in gastric polyps].
abstract: OBJECTIVE
  To explore the expression of Foxa2 in different pathological types of gastric polyps and examine the correlation with cancerous risk.
  
  
  METHODS
  According to computerize random number, a total of 2000 patients were selected to receive endoscopic biopsy during November 2011 to October 2012. Tissues were harvested from 170 with gastric polyps and suspicious cancerous lesions and their histological types detected. There were hyperplastic polyps(n = 35), adenomatous polyps(n = 31), fundic gland polyps(n = 42), advanced gastric cancer tissues (n = 32)and normal gastric mucosa tissues (n = 30). ABC immunohistochemical staining and reverse transcription(RT)-PCR were employed to detect the expression of Foxa2 in these different types of tissues. Imagepro plus was used for quantitative and statistical analyses.
  
  
  RESULTS
  A low-level expression of Foxa2 was 3.6% ± 1.3% in normal gastric mucosa group. And its expreesion gradually higher in proliferative inflammatory polyp group(33.1% ± 8.0%), adenomatous polyp group (71.4% ± 1.7%) and gastric cancer group(96.3% ± 0.9%, all P < 0.05). Its expression was 35.6% ± 5.6% in fundic gland polyps, similar to that of proliferative inflammatory polyp group (P > 0.05), it was markedly lower than the gastric cancer group (P < 0.05) and higher than the normal gastric mucosa group (P < 0.05). Correlation analyses of clinicopathological parameters showed that no significant correlation existed between its expression and patient gender, age, predilection, Helicobacter. pylori infection or proton pump inhibitor used (all P > 0.05). However, the size of polyps was correlated with Foxa2 (rs = 0.69, P < 0.05).
  
  
  CONCLUSIONS
  The expression level of Foxa2 in different types of gastric polyps may be used as a clinical predicator of polyps risk.
authors.affiliation: Department of Gastroenterology, Division of South Building, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Ning-li
authors.initials: NL
authors.lastname: Chai
authors.forename: Wen-cheng
authors.initials: WC
authors.lastname: Zhang
authors.forename: Yan-min
authors.initials: YM
authors.lastname: Wang
authors.forename: Zhao-tao
authors.initials: ZT
authors.lastname: Zhou
authors.forename: Yan-e
authors.initials: YE
authors.lastname: Zhang
authors.forename: Hong-yan
authors.initials: HY
authors.lastname: Liu
authors.forename: Jun
authors.initials: J
authors.lastname: Wan
authors.forename: Jin-hua
authors.initials: JH
authors.lastname: Qin
authors.forename: Shu-yong
authors.initials: SY
authors.lastname: Wang
authors.forename: Yun-fang
authors.initials: YF
authors.lastname: Wang
authors.forename: Xue-tao
authors.initials: XT
authors.lastname: Pei
authors.forename: Ben-yan
authors.initials: BY
authors.lastname: Wu
mesh_terms: D018256:Adenomatous Polyps / Q000378:metabolism* / Q000473:pathology*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D003430:Cross-Sectional Studies; D005260:Female; D051542:Hepatocyte Nuclear Factor 3-beta / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000378:metabolism / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor; C496502:FOXA2 protein, human; D051542:Hepatocyte Nuclear Factor 3-beta